A carbohydrate-directed heterobifunctional cross-linking reagent for the synthesis of immunoconjugates.
A novel, highly water-soluble, heterobifunctional cross-linking reagent, S-(2-thiopyridyl)-L-cysteine hydrazide (TPCH), was synthesized which contains a hydrazide moiety for coupling to aldehyde groups generated in the carbohydrate residues of antibodies by mild periodate oxidation, and a pyridyl disulfide moiety for coupling to molecules with a free sulfhydryl group. Since the carbohydrate moieties are distal to the antigen binding region of antibodies, derivatization with this cross-linker minimizes impairment of the antigen binding function. Derivatization of the human monoclonal IgM antibody 16-88 against human colon carcinoma cells with as many as 16 TPCH cross-linker molecules did not impair its antigen binding capability. Using mild oxidation conditions for antibody derivatization, sialic acid residues were identified as attachment sites for the cross-linker molecules, since after desialylation of antibody 16-88 by neuraminidase virtually no cross-linker molecules could be incorporated. Comparison of TPCH with S-(2-thiopyridyl)mercaptopropionic acid hydrazide and S-(2-thiopyridyl)-L-cysteine, two related cross-linking reagents, revealed that TPCH is most efficiently incorporated into periodate-treated antibody. Based on the structural differences of the cross-linkers, the more efficient incorporation of TPCH appears to be a function of the presence of a hydrazide moiety with an adjacent amino group. When three to four molecules of pyridyl disulfide-derivatized barley toxin were coupled to TPCH-derivatized antibody 16-88, the antigen binding capability remained uncompromised. In addition, no significant impairment of toxin activity upon coupling to the antibody was observed. Based on these data, TPCH may be very useful for the synthesis of immuno-conjugates with no or only minimal impairment of the antigen binding function.
Zara
J J
JJ
Department of Biochemistry and Molecular Biology, Georgetown University, Washington, D.C. 20007.
Wood
R D
RD
Boon
P
P
Kim
C H
CH
Pomato
N
N
Bredehorst
R
R
Vogel
C W
CW
D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000378:metabolism; D002241:Carbohydrates / Q000737:chemistry*; D003110:Colonic Neoplasms / Q000276:immunology; D003432:Cross-Linking Reagents / Q000138:chemical synthesis* / Q000737:chemistry; D003545:Cysteine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000378:metabolism; D006801:Humans; D006834:Hydrazines / Q000138:chemical synthesis / Q000378:metabolism; D000922:Immunotoxins / Q000138:chemical synthesis* / Q000737:chemistry; D011725:Pyridines / Q000138:chemical synthesis* / Q000378:metabolism; D014118:Toxins, Biological / Q000737:chemistry / Q000378:metabolism
D000911:Antibodies, Monoclonal; D002241:Carbohydrates; D003432:Cross-Linking Reagents; D006834:Hydrazines; D000922:Immunotoxins; D011725:Pyridines; D014118:Toxins, Biological; C070208:S-(2-thiopyridyl)mercaptopropionohydrazide; C070209:S-(2-thiopyridyl)cysteine hydrazide; C040150:cysteine-2-mercaptopyridine; D003545:Cysteine